RT Journal Article
T1 Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study
A1 Blanco-Ruiz, Marina
A1 Amaya-Pascasio, Laura
A1 de Torres Chacon, Reyes
A1 Josefa Alvarez Soria, Maria
A1 Arjona-Padillo, Antonio
A1 Carrillo Bailen, Maria Magdalena
A1 Milan Pinilla, Rodrigo
A1 Perez Ortega, Irene
A1 Sanchez Rodriguez, Belen
A1 Andrade Zumarraga, Luis
A1 Valverde Moyano, Roberto
A1 Payan Ortiz, Manuel
A1 Castillo Fernandez, Alba Maria
A1 Del Toro Perez, Cristina
A1 Gonzalez Bustos, Pablo
A1 Aguera Morales, Eduardo
A1 Sanchez Lopez, Purificacion
A1 Hidalgo Martin, Beatriz
A1 Roa Chamorro, Ricardo
A1 Fernandez Perez, Javier
A1 Mejias Olmedo, Maria Victoria
A1 Martinez-Sanchez, Patricia
K1 Evolocumab
K1 Alirocumab
K1 PCSK9i
K1 Hypercholesterolemia familiar
K1 Cardiovascular disease
K1 Statins intolerance
K1 Heterozygous familial hypercholesterolemia
K1 Statin therapy
K1 Double-blind
K1 Evolocumab
K1 Management
K1 Ezetimibe
K1 Trial
AB Background and aims: The benefits of the PCSK9 inhibitors, alirocumab and evolocumab, in lowering LDL-cholesterol and preventing major adverse cardiac events (MACE) have been demonstrated in pivotal clinical trials. However, few studies of routine clinical practice have been conducted to analyse and compare the efficacy and safety of the two drugs. Methods: Retrospective observational study of patients treated with a PCSK9 inhibitor in five hospitals in Andalusia (southern Spain). Baseline demographic and clinical data, LDL-cholesterol levels and the occurrence of MACEs during the follow-up period were recorded. Results: A total of 141 patients were included in the study: 90 were treated with alirocumab and 51 with evolocumab. The patients' mean age (IQR) was 58 (11) years and 58 (41%) were women. The most frequent concomitant medications were statins, 94 (66.7%), followed by antiplatelet therapy (66%) and ezetimibe (65.2%). The median (IQR) follow-up period was 18 (18) months, with 18 (24) for alirocumab and 11 (18) for evolocumab. At the six-month follow-up visit, LDL-cholesterol values had decreased to pre-treatment levels and remained significantly decreased (p
PB Elsevier
YR 2021
FD 2021-11-01
LK https://hdl.handle.net/10668/24985
UL https://hdl.handle.net/10668/24985
LA en
DS RISalud
RD Apr 10, 2025